High glucose metabolism due to GLUT1/ALDOB/G6PD axis expression promotes drug resistance in pancreatic cancer, and inhibition of the GLUT1/ALDOB/G6PD axis may serve as a target for drug resistance therapy [34]. This evidence concerns the gene G6PD and familial pancreatic carcinoma.